CAR-T cells microscopic and phenotypic identification in the peripheral blood CAR-T cells in the PB
Main Article Content
Keywords
CART-cells, lymphocyte, morphology, immunophenotyping
Abstract
CAR-T cells are a new possibility for care poor prognostic conditions. CAR-T cells injection lead to T chimeric cells circulation into the blood. Here is reported the cytomorphologic and immunophenotypic features of CAR-T cells in the peripheral blood.
Downloads
Download data is not yet available.
Abstract 908
PDF Downloads 417
HTML Downloads 149
References
1-Labanieh L, Majzner RG, Mackall CL. Programming CAR-T cells to kill cancer. Nat Biomed Eng. 2018;2(6):377-391.
doi: 10.1038/s41551-018-0235-9. Epub 2018 Jun 11.
2-Kersten MJ, Spanjaart AM, Thieblemont C. CD19-directed CAR T-cell therapy in B-cell NHL. Curr Opin Oncol. 2020;32(5):408-417.
doi: 10.1097/CCO.0000000000000668.
3 - Galli E, Bellesi S, Viscovo M, Sorà F, Hohaus S, Piccirillo N, Laurenti N, Chiusolo P, De Stefano V, Sica S, Zini G. Cytomorphology of Chimeric Antigen Receptor T-Cells (CAR-T). MediterrJ Hematol Infect Dis 2021 ;13;e2021066.
Doi: 10.4084/MJHID.2021.066
4-Yang C, Lei W, Xie H, et al. Sustained Remission of Relapsed or Refractory Mantle Cell Lymphoma After 4-1BB-Based CD19-Directed CAR-T Therapy. Onco Targets Ther. 2020;13:12163-12168.
doi: 10.2147/OTT.S280535. eCollection 2020.
5- Dana H, Chalbatani GM, Jalali SA, Mirzaei HR, Grupp SA, Suarez ER, Rapôso C, Webster TJ. CAR-T cells: Early successes in blood cancer and challenges in solid tumors. Acta Pharm Sin B. 2021 May;11(5):1129-1147.
doi: 10.1016/j.apsb.2020.10.020. Epub 2020 Nov 2.
doi: 10.1038/s41551-018-0235-9. Epub 2018 Jun 11.
2-Kersten MJ, Spanjaart AM, Thieblemont C. CD19-directed CAR T-cell therapy in B-cell NHL. Curr Opin Oncol. 2020;32(5):408-417.
doi: 10.1097/CCO.0000000000000668.
3 - Galli E, Bellesi S, Viscovo M, Sorà F, Hohaus S, Piccirillo N, Laurenti N, Chiusolo P, De Stefano V, Sica S, Zini G. Cytomorphology of Chimeric Antigen Receptor T-Cells (CAR-T). MediterrJ Hematol Infect Dis 2021 ;13;e2021066.
Doi: 10.4084/MJHID.2021.066
4-Yang C, Lei W, Xie H, et al. Sustained Remission of Relapsed or Refractory Mantle Cell Lymphoma After 4-1BB-Based CD19-Directed CAR-T Therapy. Onco Targets Ther. 2020;13:12163-12168.
doi: 10.2147/OTT.S280535. eCollection 2020.
5- Dana H, Chalbatani GM, Jalali SA, Mirzaei HR, Grupp SA, Suarez ER, Rapôso C, Webster TJ. CAR-T cells: Early successes in blood cancer and challenges in solid tumors. Acta Pharm Sin B. 2021 May;11(5):1129-1147.
doi: 10.1016/j.apsb.2020.10.020. Epub 2020 Nov 2.